细胞遗传学风险分类在移植的FLT3-ITD突变急性髓系白血病患者中保持其预后意义:代表急性白血病工作组/欧洲血液和骨髓移植学会
该研究基于欧洲血液和骨髓移植学会登记组,回顾性分析1631例接受异基因造血干细胞移植的FLT3-ITD突变急性髓系白血病患者,旨在确定细胞遗传学风险分类对结局的影响。中位年龄49岁,中位随访36个月。多因素分析显示,中危和 adverse 风险细胞遗传学患者的无白血病生存较有利风险患者显著降低,adverse 风险患者总生存显著降低,中危和 adverse 风险患者复发率更高。总体而言,细胞遗传学检查有助于细化移植后FLT3-ITD急性髓系白血病患者的风险分层。
要点
- 中危细胞遗传学患者无白血病生存较有利风险显著降低(HR=1.48,95%CI 1.06-2.06,p=.02)。
- Adverse 风险细胞遗传学患者总生存较有利风险显著降低(HR=1.74,95%CI 1.16-2.61,p=.008)。
- 中危和 adverse 风险患者复发率均较有利风险患者更高。
核心结论
- 细胞遗传学检查有助于细化接受异基因造血干细胞移植的FLT3-ITD突变急性髓系白血病患者的风险分层。
研究设计与样本
- 基于欧洲血液和骨髓移植学会登记组的回顾性分析,纳入1631例接受异基因造血干细胞移植的FLT3-ITD突变急性髓系白血病患者。
- 中位患者年龄49岁,中位随访时间36个月。
主要发现
- 2年无白血病生存率为54%,2年复发率为31.6%,非复发死亡率为14.4%,2年总生存率为60.1%。
- 多因素分析中,中危细胞遗传学患者无白血病生存较有利风险患者显著降低(HR=1.48,95%CI 1.06-2.06,p=.02)。
- Adverse 风险细胞遗传学患者无白血病生存较有利风险患者显著降低(HR=1.65,95%CI 1.13-2.40,p=.009)。
- Adverse 风险细胞遗传学患者总生存较有利风险患者显著降低(HR=1.74,95%CI 1.16-2.61,p=.008)。
- 中危细胞遗传学患者总生存较有利风险患者有降低趋势(HR=1.43,95%CI 1.00-2.05,p=.052)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutational status is a pivotal prognosticator in acute myeloid leukemia (AML) patients and significantly increases the risk of disease relapse. However, it remains unclear whether in FLT3-ITD patients referred for allogeneic stem cell transplantation (allo-SCT), baseline cytogenetics significantly impacts clinical outcome. Using the European Society of Blood and Marrow Transplantation registry, we performed a retrospective analysis of 1631 FLT3-ITD AML patients who underwent allo-SCT with the aim of determining the influence of cytogenetic risk category on patient outcomes. Median patient age was 49 years and median follow-up duration was 36 months. Two-year leukemia-free survival (LFS) and incidence of relapse were 54% and 31.6%, respectively. Non-relapse mortality was experienced by 14.4% with a 2-year overall survival (OS) of 60.1%. On multivariate analysis, LFS was significantly lower in patients with intermediate and adverse risk cytogenetics compared with those with favorable risk cytogenetics, (hazard ratio [HR] = 1.48, 95% confidence interval [CI], 1.06-2.06; p = .02), and (HR = 01.65, 95% CI, 1.13-2.40; p = .009), respectively. OS was significantly lower in patients with adverse risk cytogenetics compared with patients with favorable risk cytogenetics (HR = 1.74, 95% CI, 1.16-2.61; p = .008) with a trend toward lower OS in patients with intermediate risk cytogenetics compared to those with favorable risk cytogenetics (HR = 1.43, 95% CI, 1.00-2.05; p = .052). In addition, adverse risk patients and intermediate risk patients experienced higher relapse rates compared with favorable risk patients (HR = 1.83, 95% CI, 1.13-2.94; p = .013 and HR = 1.82, 95% CI, 1.19-2.77; p = .005). Overall, cytogenetic studies aid in refinement of risk stratification in transplanted FLT3-ITD AML patients.
引用
- Nagler A, Labopin M, Craddock C, et al. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation. Am J Hematol. 2022. PMID: 34978724. doi:10.1002/ajh.26442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。